文献速递肝肾功能剂量调整药物不良反应与药物警戒

Brensocatib单次给药在肝功能不全与肝功能正常受试者中的药代动力学与安全性

Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic Functions.
PubMed 文献 · Clin Pharmacokinet · 2026-01-26

本研究为1期、多中心、开放标签研究,纳入27例肝功能正常或轻、中、重度肝功能不全受试者,单次口服25 mg brensocatib。结果显示各肝功能组AUC与健康受试者差异≤20%,CLr为1.34-1.84 L/h对比健康受试者1.66 L/h,平均消除半衰期27.9-31.4 h,Child-Pugh评分与暴露无显著关系;TEAE发生率14.8%(4/27),多数为轻度。结论提示肝功能不全患者无需调整brensocatib剂量。

要点

  • 轻、中、重度肝功能不全者单次口服25 mg brensocatib后AUC与健康受试者差异≤20%。
  • 各肝功能组平均消除半衰期为27.9-31.4 h,肾清除率与健康受试者总体可比。
  • TEAE发生率14.8%(4/27),多数为轻度,未发现新的安全性信号。

核心结论

  • 轻、中、重度肝功能不全受试者单次口服25 mg brensocatib后口服吸收与消除未显著改变,提示肝功能不全患者无需调整剂量。
  • 未发现新的安全性信号。

研究设计与样本

  • 1期、多中心、开放标签研究,共27例受试者,按Child-Pugh数值分类为肝功能正常或轻、中、重度肝功能不全,单次口服25 mg brensocatib。
  • 采集血和尿样本评估brensocatib药代动力学、尿排泄及血浆蛋白结合。

主要发现

  • brensocatib的系统暴露(AUC)和肾清除率(CLr)在各组间总体可比,AUC与健康受试者差异≤20%,CLr为1.34-1.84 L/h对比健康受试者1.66 L/h。
  • 平均消除半衰期在各肝功能组间相似(27.9-31.4 h)。
  • 回归分析表明brensocatib系统暴露与Child-Pugh评分无显著关系。
  • 血浆中游离brensocatib随肝功能不全严重程度略有增加,游离分数(Funb)与血清白蛋白相关。
  • TEAE发生于14.8%(4/27)的受试者,多数为轻度,其中1例受试者发生2例次TEAE被认为严重。

临床怎么用

  • 基于本研究的药代动力学结果,轻、中、重度肝功能不全患者使用brensocatib时无需进行剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Brensocatib is an oral, competitive, and reversible dipeptidyl peptidase 1 (DPP1) inhibitor in development for the treatment of neutrophil-mediated diseases. Brensocatib is a substrate of CYP3A, P-glycoprotein, and breast cancer resistance protein (BCRP). Its absorption, distribution, metabolism, and elimination could be potentially affected by a decrease in hepatic function. This study evaluated the pharmacokinetics (PK), safety, and tolerability of brensocatib in participants with varying degrees of hepatic impairment and matched participants with normal hepatic function. METHODS: In this phase 1, multicenter, open-label study, 27 participants with normal hepatic function or mild, moderate, and severe hepatic impairment, based on numerical Child-Pugh classifications, received a single, oral 25-mg dose of brensocatib. Blood and urine samples were collected to evaluate brensocatib PK, urinary excretion, and plasma protein binding. RESULTS: Demographic and baseline characteristics were generally similar across hepatic impairment groups and matched healthy participants. The systemic exposure (area under the curve, AUC) and renal clearance (CLr) of brensocatib were generally comparable across all groups (≤ 20% difference in AUC compared with healthy participants and CLr 1.34-1.84 L/h versus 1.66 L/h in healthy participants). The mean elimination half-life was also similar across all hepatic function groups (27.9-31.4 h). Regression analyses indicated no significant relationships between brensocatib systemic exposure and Child-Pugh scores. Unbound brensocatib in plasma slightly increased by the severity of hepatic impairment. The fraction of unbound brensocatib (Funb) was correlated with serum albumin, suggesting that brensocatib is mainly bound to albumin in plasma. Treatment-emergent adverse events (TEAEs) occurred in 14.8% (4/27) of participants; most TEAEs were mild, and two TEAEs occurring in one participant were considered severe. No new safety findings were observed. CONCLUSIONS: No new safety signals were identified in participants with or without hepatic impairment treated with a single dose of 25 mg brensocatib. The oral absorption and elimination of brensocatib were not significantly altered in participants with mild, moderate, or severe hepatic impairment, suggesting that dose adjustment for brensocatib treatment in patients with hepatic impairment is not necessary. TRIAL REGISTRY: Clinical Trial Registration Number: NCT05517525.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Usansky H, Au Yeung S, Li S, et al. Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic Functions. Clin Pharmacokinet. 2026. PMID: 41586857. doi:10.1007/s40262-025-01614-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。